Health Care & Life Sciences » Pharmaceuticals » Orphan drugs | Therapeutic company pipeline for orphan designated drug programs US 2017

U.S. emerging therapeutic company pipeline for orphan designated drug programs 2017

Number of orphan designated products currently being developed by emerging therapeutic U.S. companies as of March 2017

The data displays the number of orphan designated drugs currently being developed by emerging therapeutic companies in the United States, as of March 2017. As of this time, of the 806 orphan programs being developed, over half were in Phase II of development.

Phase I	108	12
Phase II	393	54
Phase III	177	62

U.S. emerging therapeutic company pipeline for orphan designated drug programs 2017

StatInvestor